Table of Contents
Carbapenems are a class of broad-spectrum β-lactam antibiotics known for their effectiveness against a wide range of bacteria. They are often reserved for severe or high-risk infections, especially when other antibiotics have failed.
Overview of Carbapenems
Developed in the 1980s, carbapenems include drugs such as imipenem, meropenem, ertapenem, and doripenem. They are characterized by their resistance to most β-lactamases, enzymes produced by bacteria that confer resistance to many other β-lactam antibiotics.
Mechanism of Action
Carbapenems inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). This action leads to bacterial cell lysis and death. Their stability against β-lactamases makes them particularly effective against resistant strains.
Pharmacokinetics
Carbapenems are administered intravenously or intramuscularly. They have good tissue penetration, including cerebrospinal fluid, making them suitable for central nervous system infections. Their elimination is primarily renal, requiring dose adjustments in renal impairment.
Resistance Mechanisms
Bacterial resistance to carbapenems can develop through several mechanisms:
- Production of carbapenemases, enzymes that hydrolyze carbapenems
- Alteration of PBPs
- Efflux pump overexpression
- Reduced permeability of bacterial outer membrane
Role in Multi-drug Resistant Infections
Carbapenems are considered last-resort antibiotics for infections caused by multi-drug resistant (MDR) bacteria, especially Gram-negative pathogens such as Klebsiella pneumoniae and Pseudomonas aeruginosa. Their use has been pivotal in managing hospital-acquired infections resistant to other antibiotics.
Clinical Applications
Indications for carbapenem use include:
- Complicated intra-abdominal infections
- Nosocomial pneumonia
- Sepsis caused by resistant organisms
- Urinary tract infections
Challenges and Considerations
Increased use of carbapenems has led to the emergence of carbapenem-resistant Enterobacteriaceae (CRE), which pose a significant treatment challenge. Strategies to mitigate resistance include antimicrobial stewardship and combination therapy.
Future Perspectives
Research is ongoing to develop new β-lactamase inhibitors and novel antibiotics to overcome resistance. Combination therapies and rapid diagnostic tools are also being explored to optimize carbapenem use and limit resistance development.